Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration

Background Age‐related macular degeneration (AMD) is one of the leading causes of permanent blindness worldwide. The current mainstay of treatment for neovascular AMD (nAMD) is intravitreal injection of anti‐vascular endothelial growth factor (anti‐VEGF) agents: aflibercept, ranibizumab, and off‐lab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cochrane database of systematic reviews 2020-05, Vol.2020 (5), p.CD012208
Hauptverfasser:	Virgili, Gianni, Li, Emily, Donati, Simone, Lindsley, Kristina B, Krzystolik, Magdalena G
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Angiogenesis Inhibitors Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - economics Bevacizumab Bevacizumab - administration & dosage Bevacizumab - economics Bias Drug Administration Schedule Endophthalmitis Endophthalmitis - epidemiology Endophthalmitis - etiology Eyes & vision Humans Intravitreal Injections Intravitreal Injections - adverse effects Macular Degeneration Macular Degeneration - drug therapy Macular Degeneration - pathology Medicine General & Introductory Medical Sciences Quality of Life Randomized Controlled Trials as Topic Ranibizumab Ranibizumab - administration & dosage Ranibizumab - economics Receptors, Vascular Endothelial Growth Factor Receptors, Vascular Endothelial Growth Factor - administration & dosage Recombinant Fusion Proteins Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - economics Retina Retina - drug effects Retinal disease (including age-related macular degeneration) Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity Visual Acuity - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!